CRISPLD2 Is Expressed at Low Levels during Septic Shock and Is Associated with Procalcitonin

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Tao ^a,b   Wang, Zhi qin ^c   Wang, Lv ^b   Yan, Li ^b   Wan, Jian ^b   Zhang, Sheng ^b   Jiang, Hong quan ^c   Li, Wen fang ^b   Lin, Zhao fen ^b  

^a Hainan Branch of Chinese PLA General Hospital   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai GenePharma Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH SECRETORY PROTEIN CONTAINING LCCL DOMAIN 2; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEPTIC SHOCK; SURVIVAL RATE; UPREGULATION;

ADULT; AGED; CALCITONIN; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON REGULATORY FACTORS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; SEPSIS; SHOCK, SEPTIC; TREATMENT OUTCOME;

MUS;

EID: 84879056004     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065743     Document Type: Article

References (47)

1. Cheng B, Xie G, Yao SL, Wu X, Guo Q, et al. (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35: 2538-2546.
2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 34: 344-353.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
4. Sweet MJ, Hume DA, (1996) Endotoxin signal transduction in macrophages. J Leukoc Biol 60: 8-26.
5. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 189: 1777-82.
6. Aderem A, Ulevitch RJ, (2000) Toll-like receptors in the induction of the innate immune response. Nature 406 782-87: 10.
7. Dunn DL, Priest BP, Condie RM, (1988) Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 123: 1389-93.
8. Appelmelk BJ, Cohen J (1992) The protective role of antibodies to the lipopolysaccharide core region. In: Ryan JL, Morrison DC, eds. Bacterial endotoxin lipopolysaccharides. Vol 2. Immunopharmacology and pathophysiology. Boca Raton: CRC Press: 375-410.
9. Vreugdenhil AC, Dentener MA, Snoek AM, Greve JW, Buurman WA, (1999) Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 163: 2792-2798.
10. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, et al. (1990) Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1431.
11. Triantafilou M, Triantafilou K, (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23: 301-304.
12. Prucha M, Herold I, Zazula R, Dubska L, Dostal M, et al. (2003) Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care 7: R154-159.
13. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, et al. (1999) Relationship between plasma levels of lipopolysaccharide (LPS) and LPSbinding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 1584-1589.
14. Sakr Y, Burgett U, Nacul FE, Reinhart K, Brunkhorst F, (2008) Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med 36: 2014-2022.
15. Wang ZQ, Xing WM, Wang KS, Zhang HK, Wang QW, et al. (2009) The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin function. J Immunol 183: 6646-6656.
16. Uzzan B, Cohen R, Nicholas P, Cucherat M, Perret GY, (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34: 1996-2003.
17. Tang BMP, Eslick GD, Craig JC, McLean AS, (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7: 210-7.
18. Ruiz-Alvarez MJ, García-Valdecasas S, De Pablo R, García MS, Coca C, et al. (2009) Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 24: 63-71.
19. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman J, (1985) APACHE II: A severity of disease classification system. Crit Care Med 13: 818-829.
22. Vincent JL, Moreno R, Takala J, Willatts S, Mendonça AD, et al. (1996) The SOFA (Sepsis-related Organ Failure Assessment Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22: 707-710.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
24. Lan J, Ribeiro L, Mandeville I, Nadeau K, Bao T, et al. (2009) Inflammatory cytokines, goblet cell hyperplasia and altered lung mechanics in Lgl1+/- mice. Respir Res 10: 83.
25. Oyewumi L, Kaplan F, Sweezey NB, (2003) Lgl1, a mesenchymal modulator of early lung branching morphogenesis, is a secreted glycoprotein imported by late gestation lung epithelial cells. Biochem J 376: 61-69.
26. Oyewumi L, Kaplan F, Gagnon S, Sweezey NB, (2003) Antisense oligodeoxynucleotides decrease LGL1 mRNA and protein levels and inhibit branching morphogenesis in fetal rat lung. Am. J. Respir. Cell. Mol. Biol 28: 232-240.
27. Quinlan J, Kaplan F, Sweezey N, Goodyer PR, (2007) LGL1, a novel branching morphogen in developing kidney, is induced by retinoic acid. Am. J. Physiol. Renal. Physiol 293: F987-993.28.
28. Chiquet B T, LidralA C, Stal S, Mulliken JB, Moreno LM, et al. (2007) CRISPLD2: a novel NSCLP candidate gene. Hum. Mol. Genet 16: 2241-2248.
29. Gibbs GM, Roelants K, O'Bryan MK, (2008) The CAP Superfamily: Cysteine-Rich Secretory Proteins, Antigen 5, and Pathogenesis-Related 1 Proteins-Roles in Reproduction, Cancer, and Immune Defense. Endocrine Reviews 29: 865-897.
30. Rice L, Orlow D, Ceonzo K, Stahl GL, Tzianabos AO, et al. (2005) CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17. J Infect Dis 191(8): 1368-76.
31. Gomis S, Babiuk L, Godson DL, Allan B, Thrush T, et al. (2003) Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun 71: 857-63.
32. Waag DM, McCluskie MJ, Zhang N, Krieg AM, (2006) A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun 74: 1944-8.
33. Joerg C Schefold, (2010) Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med 36: 1810-1812.
34. Monneret G, Lepape A, Voirin N, BoheJ, Venet F, et al. (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32: 1175-1183.
35. Caille V, Chiche JD, Nciri N, Berton C, Gibot S, et al. (2004) Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 22: 521-526.
36. Boomer JS, To K, Chang CK, Takasu O, Osborne DF, et al. (2011) Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure. JAMA. December 21 306(23): 2594-2605.
37. Triantafilou M, Triantafilou K, (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23: 301-304.
38. Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM, et al. (1993) Endotoxin mediated endoth elial cell injury and activation: role of soluble CD14. Infect Immun 61: 3149-3156.
39. Gallay P, Barras C, Tobias PS, Calandra T, Glauser MP, et al. (1994) Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis 170: 1319-1322.
40. Prucha M, Herold I, Zazula R, Dubska L, Dostal M, et al. (2003) Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care 7: R154-159.
41. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, et al. (1999) Relationship between plasma levels of lipopolysaccharide (LPS) and LPS binding protein in patients with severe sepsis and septic shock. J Infect Dis 180: 1584-1589.
42. Nadeau K, Montermini L, Mandeville I, Xu M, Weiss ST, et al. (2010) Modulation of LGL1 by steroid, retinoic acid, and vitamin D models complex transcriptional regulation during alveolarization. Pediatr Res 67: 375-381.
43. Zeni F, Freeman B, Natanson C, (1997) Antiinflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25: 1095-1100.
44. Sprung CL, Annane D, Keh D, Moreno R, Singer M, et al. (2008) Hydrocortisone therapy for patients with septic shock. CORTICUS Study Group. N Engl J Med 358: 111-124.
45. Annane D, Cavillon JM, (2003) Corticosteroids in sepsis. From bench to bedside? Shock 20: 197-207.
46. Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, et al. (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System. Clin Chem Lab Med 42: 440-449.
47. Schuetz P, Christ-Crain M, Huber AR, Müller B, (2010) Long-term stability of procalcitonin in frozen samples and comparison of Kryptor® and VIDAS® automated immunoassays. Clin Biochem 43: 341-344.